

**Press Release****For Immediate Release****Glenmark enters into a settlement and license agreement with Sepracor Inc to market generic Eszopiclone tablets**

August 9, 2010 : Sepracor Inc. has entered into a settlement and license agreement with Glenmark Generics Inc., USA, Glenmark Generics Ltd., and Glenmark Pharmaceuticals Ltd. (collectively Glenmark) to resolve a United States patent infringement suit related to Glenmark's filing of an abbreviated new drug application (ANDA) with the United States Food and Drug Administration to market generic Eszopiclone tablets, which Sepracor markets under the brand name Lunesta®.

Under the terms of the settlement and license agreement, and upon approval and entry of a Consent Judgment and Order of Permanent Injunction by the United States District Court for the District of New Jersey, Glenmark would be permitted to launch its generic product on the later of November 30, 2013, which is two and one half months (2.5 months) prior to the expiry of Sepracor's United States Patent 6,444,673, or May 30, 2014 if Sepracor obtains pediatric exclusivity for Lunesta®. The settlement and license agreement and Consent Judgment and Order also would permit Glenmark to launch its generic product earlier under certain circumstances. The court's approval of the proposed Consent Judgment and Order of Permanent Injunction would dismiss Sepracor's and Glenmark's respective claims and defenses without prejudice in the consolidated litigation currently pending against Glenmark and other defendants.

Lunesta® is available in 1mg, 2mg and 3mg tablets and is indicated for the treatment of insomnia. According to IMS Health data for the 12 month period ending March 2010, Lunesta® achieved annual sales of USD 741 million and is the second highest selling branded prescription medication in its class.

**About Glenmark Generics limited.**

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader.

GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

**Disclaimer**

“Glenmark Generics Limited (“Company”) is proposing, subject to market conditions and other considerations, a public issue of its equity shares and has filed a Draft Red Herring Prospectus with SEBI. The Draft Red Herring Prospectus is available on the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in) and the respective websites of the BRLMs at [www.enam.com](http://www.enam.com) and [www.kmcc.co.in](http://www.kmcc.co.in).

Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled “Risk Factors” of the aforementioned Draft Red Herring Prospectus.”

*This press release is not an offer of securities for sale in the United States or elsewhere. The shares of Glenmark Generics Limited are not being registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. There will be no public offering of the shares in the United States.*

**NOT FOR PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA**

#####

**For further information, please contact:**

Jason D’Souza

Glenmark, Mumbai, India

Tel: [+91 22] 40189919

Email : [connect@glenmark-generics.com](mailto:connect@glenmark-generics.com)